Zacks Investment Research
23 Jun 2026, 15:51 UTC · 1h ago
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
23 Jun 2026, 15:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
The FDA has acknowledged that existing clinical data are sufficient to support the accelerated approval of Regenxbio's Navsunli for Hunter syndrome. — FDA confirmation that existing data are sufficient removes a major regulatory hurdle and significantly increases the probability of product approval.
+0.80Regenxbio plans to resubmit the biologics license application (BLA) for Navsunli in the third quarter of 2026. — Provides a concrete timeline for the next regulatory milestone, creating a catalyst window for investors.
+0.40The FDA previously issued a complete response letter (CRL) for Navsunli in February 2026, but has since lifted the clinical hold. — Contextualizes the current positive news as a recovery from a prior regulatory setback.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
FDA acknowledged existing clinical data are sufficient for accelerated approval, leading to a 16.3% share price increase.
The company received FDA accelerated approval for its treatment of Hunter Syndrome.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
